HD MEA based Neuronal Assays and Network Analysis for Phenotypic Drug Screenings
In order to overcome the limitations of existing methods for phenotypic drug screening, we propose to develop accurate, label-free, functional neuronal assays for phenotypic/functional drug screening in vitro. These assays will re...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
NEUROACT
NEUROACT A collaborative training program to develop multi...
2M€
Cerrado
EURAS
EUropean network for neurodevelopmental RASopathies
8M€
Cerrado
HumanNeuronScreen
Drug discovery screening using human neurons
150K€
Cerrado
MAPSYNE
Miniaturized automated patch clamp system combined with high...
187K€
Cerrado
3D-BrAIn
Revolutionary high-resolution human 3D brain organoid platfo...
2M€
Cerrado
Ima-Go
A High throughput Functional Imaging Platform to Accelerate...
71K€
Cerrado
Información proyecto HD-Neu-Screen
Duración del proyecto: 19 meses
Fecha Inicio: 2019-11-11
Fecha Fin: 2021-06-30
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
In order to overcome the limitations of existing methods for phenotypic drug screening, we propose to develop accurate, label-free, functional neuronal assays for phenotypic/functional drug screening in vitro. These assays will rely on the primary readout of neurons - their electrical signals. We propose to translate and commercialize the assessment of characteristic electrophysiological features of subcellular neuronal components, individual neurons and neuronal networks, all of which can be obtained with high-density microelectrode array technology (HD-MEA), into functional neuronal assays for drug screening. Most of these characteristic features have been developed in the concurrent ERC AdG neuroXscales. The model systems for the PoC will include commercially available hiPSC-derived neuronal cell lines. The PoC will be performed in collaboration with the company MaxWell Biosystems AG (http://www.mxwbio.com/), which commercializes multi-well HD-MEA platforms for use in research labs and industry.